Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDOvid Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.22 | -$0.22 | -$0.22 |
| Q2 2024 | 3 | -$0.22 | -$0.22 | -$0.22 |
| Q3 2024 | 1 | -$0.21 | -$0.21 | -$0.21 |
| Q4 2024 | 4 | -$0.18 | -$0.16 | -$0.17 |
| Q1 2025 | 2 | -$0.16 | -$0.13 | -$0.15 |
| Q2 2025 | 1 | -$0.07 | -$0.07 | -$0.07 |
| Q3 2025 | 1 | -$0.16 | -$0.16 | -$0.16 |
| Q4 2025 | 1 | -$0.16 | -$0.16 | -$0.16 |
| Q1 2026 | 1 | -$0.11 | -$0.11 | -$0.11 |
| Q2 2026 | 1 | $0.01 | $0.01 | $0.01 |
| Q3 2026 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q4 2026 | 1 | $0.01 | $0.01 | $0.01 |
Ovid Therapeutics Inc. Earnings Date And Information
Ovid Therapeutics Inc. last posted its earnings results on Tuesday, November 12th, 2024. The company reported $-0.2 earnings per share for the quarter, missing analysts' consensus estimates of $-0.19 by $0.01. The company had revenue of 173,000 for the quarter and had revenue of 391,695 for the year. Ovid Therapeutics Inc. has generated $-1 earnings per share over the last year ($-0.74 diluted earnings per share) and currently has a price-to-earnings ratio of -2.12. Ovid Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based on prior year's report dates.
Ovid Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/12/2024 | Q3 2024 | -$0.19 | -$0.20 | -0.01 | $105,500 | $173,000 |
| 08/13/2024 | Q2 2024 | -$0.22 | $0.12 | 0.34 | $65,375 | $169,000 |
| 05/14/2024 | Q1 2024 | -$0.23 | -$0.17 | 0.06 | $148,000 | |
| 03/08/2024 | Q4 2023 | -$0.17 | -$0.22 | -0.05 | $141,562 | |
| 11/03/2023 | Q3 2023 | -$0.18 | -$0.16 | 0.02 | $45,833 | $108,972 |
| 08/04/2023 | Q2 2023 | -$0.21 | -$0.18 | 0.03 | $47,750 | $75,000 |
| 05/05/2023 | Q1 2023 | -$0.18 | $21.60 | 21.78 | $66,160 | |
| 03/13/2023 | Q4 2022 | -$0.19 | -$0.16 | 0.03 | $46,280 | |
| 11/08/2022 | Q3 2022 | -$0.21 | -$0.16 | 0.05 | $11,102 | |
| 08/09/2022 | Q2 2022 | -$0.23 | -$0.21 | 0.02 | $0 | |
| 05/10/2022 | Q1 2022 | $1.17 | -$0.23 | -1.4 | $1.45 M | |
| 03/15/2022 | Q4 2021 | -$0.17 | -$0.39 | -0.22 | $-416,348,792 | |
| 11/10/2021 | Q3 2021 | -$0.19 | -$0.17 | 0.02 | $0 | |
| 08/13/2021 | Q2 2021 | -$0.15 | -$0.23 | -0.08 | $0 | |
| 05/13/2021 | Q1 2021 | $1.68 | $2.55 | 0.87 | $208.38 M | |
| 03/15/2021 | Q4 2020 | -$0.31 | -$0.35 | -0.04 | $5.70 M | |
| 11/12/2020 | Q3 2020 | -$0.28 | $100,000 | $6.91 M | ||
| 08/10/2020 | Q2 2020 | -$0.38 | -$0.41 | -0.03 | $0 | |
| 05/07/2020 | Q1 2020 | -$0.34 | -$0.37 | -0.03 | $0 | |
| 03/11/2020 | Q4 2019 | -$0.46 | -$0.35 | 0.11 | $0 |
Ovid Therapeutics Inc. Earnings: FAQ's
When is Ovid Therapeutics Inc.'s earnings date?
Ovid Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based off last year's report dates.
How can I listen to Ovid Therapeutics Inc.'s earnings conference
call?
The conference call for Ovid Therapeutics Inc.'s latest earnings report can be listened to online.
How can I read Ovid Therapeutics Inc.'s conference call transcript?
The conference call transcript for Ovid Therapeutics Inc.'s latest earnings report can be read online.
How much revenue does Ovid Therapeutics Inc. generate each year?
Ovid Therapeutics Inc. (:OVID) has a recorded annual revenue of $391,695.
How much profit does Ovid Therapeutics Inc. generate each year?
Ovid Therapeutics Inc. (:OVID) has a recorded net income of $391,695. Ovid Therapeutics Inc. has generated $-0.74 earnings per share over the last four quarters.
What is Ovid Therapeutics Inc.'s price-to-earnings ratio?
Ovid Therapeutics Inc. (:OVID) has a price-to-earnings ratio of -2.12 and price/earnings-to-growth ratio is 0.23.